China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
94 hedge funds and large institutions have $1.69B invested in China Biologic Products Holdings, Inc. in 2017 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 43 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
5% less call options, than puts
Call options by funds: $2.61M | Put options by funds: $2.74M
21% less funds holding
Funds holding: 119 → 94 (-25)
25% less capital invested
Capital invested by funds: $2.25B → $1.69B (-$565M)
53% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 43
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$49.3M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$45.3M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$26.9M |
| 4 |
CGI
Comgest Global Investors
Paris,
France
|
+$19.7M |
| 5 |
NSRI
New Silk Road Investment
Singapore
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$88M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$82.1M |
| 3 |
BlackRock
New York
|
-$67.4M |
| 4 |
ICP
Indus Capital Partners
New York
|
-$31.5M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$25.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OAM
126
Oberweis Asset Management
Lisle,
Illinois
| – | -$339K | -3,000 | Closed |
|
|
MC
127
Martin Currie
Edinburgh,
United Kingdom
| – | -$192K | -1,700 | Closed |
|
|
OAM
128
Oppenheimer Asset Management
New York
| – | -$171K | -1,512 | Closed |
|
|
FMT
129
First Mercantile Trust
Cordova,
Tennessee
| – | -$136K | -1,200 | Closed |
|
|
DI
130
DUMAC Inc
Durham,
North Carolina
| – | -$105K | -932 | Closed |
|
|
ST
131
Smithfield Trust
Pittsburgh,
Pennsylvania
| – | -$56K | -499 | Closed |
|
|
GXMC
132
Global X Management Company
New York
| – | -$30K | -266 | Closed |
|
|
SIAS
133
Shine Investment Advisory Services
Lone Tree,
Colorado
| – | -$21K | -188 | Closed |
|
|
AIM
134
Acrospire Investment Management
Chicago,
Illinois
| – | -$21K | -184 | Closed |
|
|
DADC
135
D.A. Davidson & Co
Great Falls,
Montana
| – | -$11K | -100 | Closed |
|
136
Lazard Asset Management
New York
| – | -$11K | -100 | Closed |
|
|
TRCT
137
Tower Research Capital (TRC)
New York
| – | -$4K | -39 | Closed |
|
CBPO Hedge Fund Activity: Q3 2017 in Review
94 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q3 2017, worth a combined $1.69B — down 25% from $2.25B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of CBPO and 20 opened new positions — a net loss of 23 holders — while 29 trimmed existing stakes and 39 added.
The largest buyer was Vanguard Group, adding an estimated $49.3M. The largest seller was Capital World Investors, exiting entirely with an estimated $88M sold.
- 94 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q3 2017, down from 119 in Q2 2017.
- Funds reported $1.69B of China Biologic Products Holdings, Inc. stock for Q3 2017, down 25% quarter-over-quarter.
- 20 funds opened new China Biologic Products Holdings, Inc. positions in Q3 2017 and 43 closed out, a net change of -23 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q3 2017 was Vanguard Group, an estimated $49.3M added.
- The largest China Biologic Products Holdings, Inc. seller in Q3 2017 was Capital World Investors, an estimated $88M sold.
Based on aggregated 13F filings for Q3 2017.